Table 2. Antibiotic use, treatment failures, and adverse events for study patients at baseline and during intervention Period 1 and Period 2.
P value | |||||
Outcome | BaselineN = 200 | Period 1N = 200 | Period 2N = 200 | Baseline-Period 1 | Period 1-Period 2 |
Mean duration of therapy for cystitisa (days) | 5.6 | 3.9 | 3.6 | <.001 | .17 |
Percentage of fluoroquinolone regimens for cystitis | 44.4 | 14.5 | 12.9 | <.001 | .70 |
Unnecessary antibiotic days of therapy, total | 250 | 119 | 52 | <.001 | <.001 |
Treatment failureb | 22 (11.0) | 14 (7.0) | 17 (8.5) | .16 | .58 |
Primary adverse eventsc | 12 (6) | 17 (8.5) | 19 (9.5) | .66 | .59 |
Other adverse eventsd | 49 (24.5) | 54 (27) | 47 (23.5) | .54 | .52 |
Including only trimethoprim-sulfamethoxazole and ciprofloxacin containing regimens.
A change in the initially prescribed UTI treatment regimen within 2 weeks of prescription due to clinical failure, isolation of a resistant organism, or adverse effects.
Including allergic reactions, gastrointestinal side effects, and vaginal yeast infections occurring within 8 weeks of treatment and felt to be related to the antibiotic prescribed for UTI.
Including return visits to the ED or other hospital sites for persistence of UTI symptoms or for additional treatment for alternative diagnoses related to UTI symptoms, missed STI diagnoses, or for treatment of a recurrent UTI (separate from initial UTI) occurring within 8 weeks of the initial ED visit.